Dr Martens consensus estimates may be too optimistic, says RBC Capital
RBC Capital Markets cut its price target on Dr Martens on Monday to 60p form 70p and reduced its revenue and earnings per share estimates, saying that consensus estimates may be too optimistic.
The bank, which rates the shares at 'sector perform', said it expects Dr Martens to deliver FY25 results largely in line with consensus and guidance, after a year of reducing inventories and debt, preserving cash and stabilising the business overall.
"Looking ahead, we anticipate a return to positive revenue growth (+5%) and incremental margin rebuild to 10% in FY26E, however our earnings per share estimates are circa 20% below consensus," it said.
RBC said that given its relatively small size, the longer-term growth prospects for DOCS should remain healthy. This is supported by store roll-out, franchisee conversions, and increasing direct-to-consumer mix, as well as improving the quality and depth of wholesale distribution.
"However, FY26E consensus expectations appear too elevated and risk/reward appears balanced to us at this stage," it said.
At 1100 BST, the shares were down 7.2% at 56.65p.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.